Literature DB >> 7722546

Patterns of comorbidity in elderly patients with multiple sclerosis.

S T Fleming1, R L Blake.   

Abstract

This study explored the prevalence of comorbid conditions in hospitalized patients with multiple sclerosis (MS) who were 65 years of age or older. Using 1989 data from the Quality of Care Medicare Provider Analysis and Review (MEDPAR) file, hospitalized MS patients were compared with respect to discharge diagnoses to an age- and sex-matched group of hospitalized patients without MS. As expected, the following discharge diagnoses were more common (P < 0.05) for MS patients: urinary tract infection, pneumonia, septicemia and cellulitus. In contrast, MS patients were less likely (P < 0.05) to have discharge diagnoses of acute myocardial infarction, heart failure, hypertension, angina pectoris, cerebrovascular disease, diabetes mellitus and chronic obstructive pulmonary disease. Possible explanations include under-reporting of certain comorbid conditions on discharge records of MS patients, a protective effect of MS or its treatment, reduced prevalence of risk factors, disproportionate mortality in younger MS patients with comorbidity and the benefits of medical surveillance.

Entities:  

Mesh:

Year:  1994        PMID: 7722546     DOI: 10.1016/0895-4356(94)90099-x

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  14 in total

Review 1.  Cardiac spectroscopy: techniques, indications and clinical results.

Authors:  Meinrad Beer
Journal:  Eur Radiol       Date:  2004-03-06       Impact factor: 5.315

Review 2.  Multiple sclerosis in the elderly patient.

Authors:  Amer Awad; Olaf Stüve
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

3.  Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.

Authors:  Anja Thormann; Melinda Magyari; Nils Koch-Henriksen; Bjarne Laursen; Per Soelberg Sørensen
Journal:  J Neurol       Date:  2016-10-03       Impact factor: 4.849

4.  Dramatically changing rates and reasons for hospitalization in multiple sclerosis.

Authors:  Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; James Blanchard; Aruni Tennakoon; Nancy Yu
Journal:  Neurology       Date:  2014-08-01       Impact factor: 9.910

5.  The development of primary central nervous system B-cell lymphoma in multiple sclerosis.

Authors:  Mark K Lyons; Orland K Boucher; Barry D Birch; Naresh P Patel
Journal:  Neurohospitalist       Date:  2011-07

Review 6.  A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis.

Authors:  Ruth Ann Marrie; Nadia Reider; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Gary Cutter; Stephen Reingold; Per Soelberg Sorensen
Journal:  Mult Scler       Date:  2014-12-22       Impact factor: 6.312

Review 7.  The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review.

Authors:  Ruth Ann Marrie; Nadia Reider; Olaf Stuve; Maria Trojano; Per Soelberg Sorensen; Gary R Cutter; Stephen C Reingold; Jeffrey Cohen
Journal:  Mult Scler       Date:  2014-12-23       Impact factor: 6.312

Review 8.  A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis.

Authors:  Ruth Ann Marrie; Nadia Reider; Jeffrey Cohen; Olaf Stuve; Per S Sorensen; Gary Cutter; Stephen C Reingold; Maria Trojano
Journal:  Mult Scler       Date:  2014-12-22       Impact factor: 6.312

Review 9.  A systematic review of the incidence and prevalence of cancer in multiple sclerosis.

Authors:  Ruth Ann Marrie; Nadia Reider; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sorensen; Stephen C Reingold; Gary Cutter
Journal:  Mult Scler       Date:  2014-12-22       Impact factor: 6.312

10.  Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.

Authors:  Victor M Rivera; Douglas R Jeffery; Bianca Weinstock-Guttman; Daena Bock; Fernando Dangond
Journal:  BMC Neurol       Date:  2013-07-11       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.